Cinqair
Total Payments
$773,463
Transactions
535
Doctors
28
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $773,463 | 535 | 28 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $773,048 | 512 | 99.9% |
| Food and Beverage | $415.34 | 23 | 0.1% |
Payments by Type
Research
$773,048
512 transactions
General
$415.34
23 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma | Teva Pharmaceuticals USA, Inc. | $397,850 | 3 |
| A 52-Week Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Reslizumab 110 mg Fixed, Subcutaneous Dosing in Patients With Uncontrolled Asthma and Elevated Blood Eosinophils | Teva Pharmaceuticals USA, Inc. | $273,882 | 3 |
| Reslizumab in the Treatment of EGPA | Teva Pharmaceuticals USA, Inc. | $69,494 | 0 |
| A Phase 3, 24-Week Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Reslizumab Subcutaneous Dosing (110 mg Every 4 Weeks) in Patients With Oral Corticosteroid Dependent Asthma and Elevated Blood | Teva Pharmaceuticals USA, Inc. | $30,733 | 0 |
| An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients With Eosinophilic Asthma Who Completed a Prior Teva-Sponsored Study in Eosinophilic Asthma | Teva Pharmaceuticals USA, Inc. | $837.75 | 0 |
| A Single-Dose, Open-Label, Parallel Group Study to Characterize the Pharmacokinetics, Pharmacodynamics, Immunogenicity, Safety, and Tolerability of Reslizumab Following Subcutaneous Administration in Children with Asthma (6 to Less Than 12 Years of Age) | Teva Pharmaceuticals USA, Inc. | $250.00 | 0 |
Top Doctors Receiving Payments for Cinqair
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Miami, FL | $749,673 | 493 |
| , M.D | Internal Medicine | Abingdon, VA | $9,444 | 9 |
| , MD | Allergy & Immunology | Huntington Beach, CA | $7,903 | 2 |
| , MD | Allergy & Immunology | Tallahassee, FL | $5,453 | 6 |
| , M.D | Allergy & Immunology | Narberth, PA | $300.00 | 1 |
| , MD | Pediatric Pulmonology | Oklahoma City, OK | $275.00 | 1 |
| , M.D | Otolaryngology | Bronx, NY | $28.71 | 1 |
| , M.D | Otolaryngology | Bronx, NY | $28.71 | 1 |
| , MD | Otolaryngology | Bronx, NY | $28.71 | 1 |
| , MD | Allergy & Immunology | Bronx, NY | $28.70 | 1 |
| , M.D | Otolaryngology | Bronx, NY | $28.70 | 1 |
| , FAMILY NURSE PRACTIT | Allergy & Immunology | Tarrytown, NY | $20.00 | 1 |
| , M.D | Allergy | Tarrytown, NY | $20.00 | 1 |
| , MD | Allergy & Immunology | San Diego, CA | $19.52 | 1 |
| , M. D | Allergy & Immunology | San Diego, CA | $19.52 | 1 |
| , MD | Pulmonary Disease | Bronx, NY | $18.13 | 1 |
| , M.D | Internal Medicine | Brooklyn, NY | $18.13 | 1 |
| , M.D | Gastroenterology | New York, NY | $18.13 | 1 |
| , MD | Pulmonary Disease | New York, NY | $18.13 | 1 |
| , M.D | Otolaryngology | Bronx, NY | $15.73 | 1 |
| , M.D | Allergy | Bronx, NY | $14.00 | 1 |
| , M.D | Internal Medicine | New York, NY | $14.00 | 1 |
| , MD | Otolaryngology | Bronx, NY | $13.67 | 1 |
| , D.O | Allergy & Immunology | Brooklyn, NY | $13.66 | 1 |
| , MD, PHD | Allergy & Immunology | Omaha, NE | $11.17 | 1 |
Ad
Manufacturing Companies
- Teva Pharmaceuticals USA, Inc. $773,463
Product Information
- Type Drug
- Total Payments $773,463
- Total Doctors 28
- Transactions 535
About Cinqair
Cinqair is a drug associated with $773,463 in payments to 28 healthcare providers, recorded across 535 transactions in the CMS Open Payments database. The primary manufacturer is Teva Pharmaceuticals USA, Inc..
Payment data is available from 2018 to 2018. In 2018, $773,463 was paid across 535 transactions to 28 doctors.
The most common payment nature for Cinqair is "Unspecified" ($773,048, 99.9% of total).
Cinqair is associated with 6 research studies, including "An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma" ($397,850).